Alphyn Doses First Patients in CLEAR-AD1 Global Phase 2b Clinical Trial Program for Atopic Dermatitis

/PRNewswire/ — Alphyn GmbH, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that it has initiated…Read More